TTA-A2 NEW
| Price | $106 | $268 | $428 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-05-12 |
Product Details
| Product Name: TTA-A2 | CAS No.: 953778-63-7 |
| Purity: 99.9% | Supply Ability: 10g |
| Release date: 2025/05/12 |
Product Introduction
Bioactivity
| Name | TTA-A2 |
| Description | TTA-A2 is a selective T-type calcium channel antagonist as a potent anticonvulsant that the Cav3.1 isoform plays a prominent role in mediating. TTA-A2 is equally potent against the Cav3.1 (a1G) and Cav3.2 (a1H) channels with IC50 values of 89 nM and 92 nM, respectively, at -80 and -100 mV holding potentials. TTA-A2 can be used for the research of a variety of human neurological diseases, including sleep disorders and epilepsy. |
| In vivo | TTA-A2 (oral gavage; 10 mg/kg; once daily; 5 days) shows selective effect on recurrent thalamocortical network activity, it suppresses active wake and promotes slow-wave sleep in wild-type mice but not in mice lacking both Cav3.1 and Cav3.3[1].TTA-A2 (oral gavage;?3 mg/kg;?single dose) produces significant changes in sleep architecture in rats.?A reduction in active wake soon after dosing with a concurrent increase in delta sleep and decrease in REM sleep.?Additionally, these effects persists for up to 4 h post-dose in rats[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 27.5 mg/mL (72.68 mM), Sonication is recommended. |
| Keywords | T-type calcium channel | TTA-A-2 | TTA-A2 | TTAA2 | TTA A2 | sleep disorders | Pregnane X receptor | neurological diseases | Inhibitor | inhibit | Epilepsy | Electrocorticogram | Cav3.2 (a1H) | Cav3.1 (a1G) | CalciumChannel | Calcium Channel | Ca2+ channels | Ca channels |
| Inhibitors Related | Nisoldipine | Diltiazem hydrochloride | Levetiracetam | L-Ascorbic acid | L-Phenylalanine | D-Menthol | Ethyl cinnamate | L-Ascorbic acid sodium salt | 1-Octanol | 2-Nitrobenzoic acid | Nifedipine | Otilonium bromide |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Inhibitor Library | Neuroprotective Compound Library | Anti-Cardiovascular Disease Compound Library | NO PAINS Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Ion Channel Targeted Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1g |
VIP5Y
|
XIAMEN SINOPEG BIOTECH CO., LTD.
|
2024-07-30 | |
| $3520.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2025-04-30 | |
| $0.00/1kg |
VIP4Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2025-05-12 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY